

FOCUSED ON HIGH UNMET NEED IN PARKINSON'S DISEASE

A clinical-stage specialty pharmaceutical developer with a proprietary R&D platform and database delivering IPR and drug candidates

SALSS CONTACT

Nicholas Waters
CEO

nicholas.waters@irlab.se
+ 46 (0) 730 75 77 01

IRLAB Therapeutics AB
Arvid Wallgrens Backe 20
Gothenburg, 413 46
Sweden

www.irlab.se

SALSS PRESENTING COMPANY | 2018



IRLAB Therapeutics AB | Nasdaq First North Premier: IRLAB A

IRLAB Therapeutics, based in Gothenburg, is a clinical-stage, publicly listed R&D company focused on CNS disorders and addressing unmet needs in Parkinson's disease (PD). It has a proprietary R&D platform and database, the integrative screening process (ISP) to enhance translational value through phenotypic screening and systems pharmacology. Its two lead programs, IRL752 and IRL790 are currently in Phase II.

OUR PRODUCTS & SERVICES

Parkinson's disease affects about 6 million individuals worldwide and is the fastest growing neurological disorder. No effective disease-modifying treatments exist and thus the unmet medical need is huge.

IRLAB has two clinical-stage lead programmes and a pre-clinical stage pipeline.

- **IRL752** is a cortical enhancer for the treatment of Parkinson Disease Dementia (PD-D) and Behavioral and Psychological Symptoms of Dementia (BPSD). Top-line results from a 40 patient Phase IIa study completed in Q2 2018 have shown that IRL752 was well tolerated, meeting the primary endpoint.
- **IRL790** is a psychomotor stabilizer for the treatment of L-dopa induced dyskinesias in Parkinson's Disease (PD-LIDs) and Parkinson Disease psychosis (PD-P). IRL790 displayed good safety in Phase Ib and IRLAB received approval from the UK MHRA to conduct a Phase II study with the drug candidate IRL790 for treatment of LIDs in about 74 patients, with top line data from this study expected in Q3 of 2018.

WHAT MAKES US UNIQUE

IRLAB has a highly differentiated *in vivo* systems response profiling approach to discovery, based on phenotypic screening to enhance translational mapping, a crucial issue in CNS drug discovery.

Our approach maps *in vivo* profiles of CNS compounds, based on dose response studies. Applying a systematic and standardized work-flow, a database of *in vivo* systems response profiles is compiled, enabling comparisons and classification. The resultant biological response profile, treated as an array, is used as major outcome for selection of candidate drugs.

WHY YOU SHOULD MEET US

IRLAB is looking to further expand its shareholder base as it aims towards the Main Market. It is also evaluating partnering at key transition points in its pipeline, as it progresses its first-in-class compounds through clinical trials.

KEY TEAM

Nicholas Waters, PhD

- CEO
- Formerly CEO of NeuroSearch Sweden, and CEO, and co-founder and CSO of Carlsson Research

Clas Sonesson, PhD

- CSO
- Formerly Head of Discovery and VP, Chemistry & IP at NeuroSearch Sweden

Joakim Tedroff, MD, PhD

- CMO
- Practising neurologist specialist in neurodegenerative disorders

Viktor Siewertz, LL.M, MSc

- CFO (& former COO)
- Formerly HSH Nordbank, Handelsbanken, Consensus Asset Management

Susanna Holm Waters, MD, PhD

- Dir. Biology & Biostatistics
- Co-founder, Carlsson & IRLAB

Peder Svensson, PhD

- Dir. Computational Biology
- AstraZeneca, CR, Neurosearch

SWEDISH
AMERICAN
LIFE SCIENCE
SUMMIT
2018